OnCo
ideasIdea

A university cyclotron network with shared regulatory files for new tracers

Most new cancer imaging agents and radioactive drugs start in university hospitals. A network sharing production, quality files and regulatory paperwork would get them into multi-centre trials years faster.

Academic radiopharmacy has repeatedly produced the field's most important agents (PSMA ligands and FAPI tracers from Heidelberg, DOTATATE from Basel and Rotterdam) but each centre re-creates production, quality control and regulatory documentation. A funded network of university cyclotrons and radiopharmacies would share drug master files, validated synthesis modules, GMP quality systems and a common clinical trial application template, so a tracer validated in one centre can be adopted in ten within months. It would also provide isotope purchasing at scale (gallium-68 generators, lutetium-177, actinium-225 allocation) for academic trials.

Hypothesis
A shared network reduces the time from first-in-human of an academic tracer or radioligand to a five-centre trial from the current several years to under eighteen months, and doubles the number of academic radiopharmaceuticals entering multi-centre trials within four years.
Rationale
PSMA PET spread globally because academic centres shared precursors and methods informally; formalising that with shared regulatory files removes the largest delay. Germany's and the Netherlands' academic radiopharmacy networks demonstrate feasibility within a country.
What would test it
Fund a ten-centre network with a shared master file for two agents and measure time to multi-centre trial start and centres activated compared with agents developed without the network.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

15top

Pages like this

not linked directly; found by shared links

technologies

4
FAPI PETPSMA PETRadioligand therapy (beta emitters)Targeted alpha therapy

institutions

3
German Cancer Research Center (DKFZ)Heidelberg University Hospital / NCT / DKFZPeter MacCallum Cancer Centre

roadmaps

1
Radiopharmaceutical roadmap: iodine → lutetium → actinium

ideas

2
A phase 0 fund to test academic compounds in humans with microdoses and imagingFAP theranostics as a pan-cancer stromal strategy

people

3
Frederik GieselMichael HofmanUwe Haberkorn

bottlenecks

2
Manufacturing cost and time for living and radioactive medicinesThe valley of death between lab and product